Published in Respiratory Therapeutics Week, October 3rd, 2005
According to a study from Netherlands, "Tumor necrosis factor-alpha is believed to be important in the induction and maintenance of airway inflammation in chronic obstructive pulmonary disease. We aimed to evaluate the effect of the anti-tumor necrosis factor-a drug infliximab in patients with chronic obstructive pulmonary disease, with percentage of sputum neutrophils as the primary endpoint."
"We performed an exploratory single-center, double-blind, placebo-controlled, randomized, phase 2 trial in which 22 current smokers with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Respiratory Therapeutics Week